Thymalin: Research Overview

Thymalin is a polypeptide complex originally extracted from the thymus glands of calves. It was developed in the Soviet Union and Russia beginning in the 1970s, primarily at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson. It has been registered as a pharmaceutical drug in Russia and continues to be used there clinically. Outside Russia, Thymalin is available mainly through research-chemical vendors and is not approved for human use by the FDA, EMA, or other Western regulatory bodies. Researchers and reviewers evaluating this compound should be aware that the evidence base is concentrated in one research group and predominantly published in Russian-language or Russian-affiliated journals.

What Is Thymalin?

Thymalin is not a single synthetic peptide but a complex preparation of low-molecular-weight polypeptides isolated from calf thymus tissue. Its active fractions include short peptide sequences such as Lys-Glu (vilon), Glu-Trp, and Glu-Asp-Pro (EDP). Because it is a natural extract rather than a fully characterized synthetic molecule, batch composition can vary. It is classified as a thymic bioregulator — a category of compounds posited by the Khavinson group to normalize the function of tissues from which they are derived.

Mechanism

The proposed mechanism of Thymalin centers on the short peptide constituents in its composition acting as epigenetic and transcriptional regulators. In cell culture studies, constituent peptides promoted differentiation of hematopoietic stem cells, increased expression of the T-cell maturation marker CD28 by approximately 6.8-fold, and reduced expression of progenitor markers CD44 and CD117. A 2021 study published in Advances in Gerontology (PMC8654498) reported that Thymalin's immunoprotective action in COVID-19 patients was attributed to these short peptides modulating lymphocyte subsets and reducing systemic inflammatory markers. The mechanistic picture remains incomplete; most studies are in vitro or in small clinical cohorts.

What the Research Shows

The most-cited evidence for Thymalin comes from a longitudinal study by Khavinson and Morozov (PMID 14523363) that followed 266 elderly patients over 6–8 years. Patients treated with Thymalin showed a 2.0–2.1-fold reduction in mortality compared to controls; patients receiving combined Thymalin and Epithalamin showed a 4.1-fold reduction over 6 years of annual treatment. These findings are striking but have important limitations: the study was open-label, conducted by the same group that developed the product, and to date has not been independently replicated in a Western peer-reviewed randomized controlled trial.

A more recent 2021 single-blind randomized controlled trial (PMC8654498) enrolled 80 patients with severe COVID-19 — 36 receiving Thymalin (10 mg IM daily for 10 days) plus standard care vs. 44 receiving standard care only. The Thymalin group showed faster normalization of lymphocyte counts, C-reactive protein, and D-dimer levels, and a lower in-hospital mortality. This is a single-center Russian study and should be interpreted cautiously pending replication. No large-scale multi-center trials have been published as of 2026.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Published dose-finding studies are limited; values reported here come from Russian clinical literature and have not been validated in modern clinical trials. The COVID-19 study cited above used 10 mg intramuscularly once daily for 10 days. Earlier Khavinson longevity protocols reportedly used 5–10 mg IM daily for 5–10 days, repeated 1–2 times per year. Oral and sublingual formulations are sold by some vendors, but no published pharmacokinetic data supports oral bioavailability of the peptide fractions.

References

1. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-240. PMID 14523363.

2. Khavinson V et al. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Adv Gerontol. 2021;11(4):357-365. PMC8654498.

3. Khavinson V et al. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020;170(2):241-244. PMC7686446.